Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 31,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $1.65, for a total value of $51,150.00. Following the completion of the sale, the insider directly owned 48,750 shares of the company’s stock, valued at $80,437.50. This represents a 38.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daljit Singh Aurora also recently made the following trade(s):

• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total value of $51,014.70.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total value of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total value of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA remained flat at $1.64 during trading on Wednesday. The stock had a trading volume of 716,090 shares, compared to its average volume of 699,708. The company has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $2.11. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 5.09. Neumora Therapeutics, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. As a group, equities analysts forecast that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Mizuho cut their price target on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, June 18th. Needham & Company LLC decreased their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Weiss Ratings cut shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. Finally, Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.57.

Key Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from $1.29 and its FY2027 forecast to a loss of $0.68 from $1.25, indicating analysts expect substantially narrower losses over the next two years.
• Positive Sentiment: The firm also improved its quarterly outlook, forecasting a Q3 2026 loss of $0.20 per share versus $0.32 previously and a Q4 2026 loss of $0.16 versus $0.30 previously.
• Positive Sentiment: Longer-term estimates were upgraded sharply: FY2028’s projected loss narrowed to $0.52 from $1.10, FY2029 moved to projected profit of $0.20 from a $0.26 loss, and FY2030 profit expectations increased to $1.83 from $1.51 per share. These changes imply a faster potential transition to profitability.
• Positive Sentiment: HC Wainwright’s current estimates call for losses of $0.15, $0.16, $0.19 and $0.17 per share in the first four quarters of 2027, respectively, with full-year 2027 losses of $0.68. The firm’s continued Buy rating provides additional support for investor sentiment.
• Neutral Sentiment: Neumora remains unprofitable, with the broader current-year consensus at a loss of $0.93 per share. The company’s shares are trading well below their 200-day moving average and remain near the lower portion of their 12-month range, underscoring continued execution and financing risks despite the improved forecasts.

Hedge Funds Weigh In On Neumora Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Neumora Therapeutics during the second quarter worth about $13,246,000. Perceptive Advisors LLC acquired a new stake in shares of Neumora Therapeutics in the first quarter valued at about $9,953,000. ICONIQ Capital LLC acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at about $4,350,000. Siren L.L.C. raised its holdings in shares of Neumora Therapeutics by 35.1% during the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after buying an additional 2,209,039 shares during the period. Finally, Johnson & Johnson purchased a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at about $3,144,057,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.